257 related articles for article (PubMed ID: 36361924)
1. 4-Thiazolidinone-Bearing Hybrid Molecules in Anticancer Drug Design.
Roszczenko P; Holota S; Szewczyk OK; Dudchak R; Bielawski K; Bielawska A; Lesyk R
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361924
[TBL] [Abstract][Full Text] [Related]
2. Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues.
de Siqueira LRP; de Moraes Gomes PAT; de Lima Ferreira LP; de Melo Rêgo MJB; Leite ACL
Eur J Med Chem; 2019 May; 170():237-260. PubMed ID: 30904782
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinone-Heterocycle Frameworks: A Concise Review of Their Pharmacological Significance.
Seboletswe P; Cele N; Singh P
ChemMedChem; 2023 Apr; 18(7):e202200618. PubMed ID: 36694980
[TBL] [Abstract][Full Text] [Related]
4. Synthetic approaches, structure activity relationship and biological applications for pharmacologically attractive pyrazole/pyrazoline-thiazolidine-based hybrids.
Havrylyuk D; Roman O; Lesyk R
Eur J Med Chem; 2016 May; 113():145-66. PubMed ID: 26922234
[TBL] [Abstract][Full Text] [Related]
5. Natural product-inspired synthesis of thiazolidine and thiazolidinone compounds and their anticancer activities.
Zhang Q; Zhou H; Zhai S; Yan B
Curr Pharm Des; 2010 Jun; 16(16):1826-42. PubMed ID: 20337578
[TBL] [Abstract][Full Text] [Related]
6. 5-Ene-4-thiazolidinones - An efficient tool in medicinal chemistry.
Kaminskyy D; Kryshchyshyn A; Lesyk R
Eur J Med Chem; 2017 Nov; 140():542-594. PubMed ID: 28987611
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and anticancer activity of novel 4-thiazolidinone-phenylaminopyrimidine hybrids.
Türe A; Ergül M; Ergül M; Altun A; Küçükgüzel İ
Mol Divers; 2021 May; 25(2):1025-1050. PubMed ID: 32328961
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel pyridine-thiazolidinone derivatives as anticancer agents: Targeting human carbonic anhydrase IX.
Ansari MF; Idrees D; Hassan MI; Ahmad K; Avecilla F; Azam A
Eur J Med Chem; 2018 Jan; 144():544-556. PubMed ID: 29289880
[TBL] [Abstract][Full Text] [Related]
9. Tubulin inhibitors. Selected scaffolds and main trends in the design of novel anticancer and antiparasitic agents.
Podolak M; Holota S; Deyak Y; Dziduch K; Dudchak R; Wujec M; Bielawski K; Lesyk R; Bielawska A
Bioorg Chem; 2024 Feb; 143():107076. PubMed ID: 38163424
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel 4-thiazolidinone derivatives with promising anti-breast cancer activity: Synthesis, characterization, in vitro and in vivo results.
Tahmasvand R; Bayat P; Vahdaniparast SM; Dehghani S; Kooshafar Z; Khaleghi S; Almasirad A; Salimi M
Bioorg Chem; 2020 Nov; 104():104276. PubMed ID: 32992280
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of imidazopyridine-linked thiazolidinone as potential anticancer agents.
Iqbal MA; Husain A; Alam O; Khan SA; Ahmad A; Haider MR; Alam MA
Arch Pharm (Weinheim); 2020 Oct; 353(10):e2000071. PubMed ID: 32627909
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Anticancer and Antibacterial Activity of Four 4-Thiazolidinone-Based Derivatives.
Skóra B; Lewińska A; Kryshchyshyn-Dylevych A; Kaminskyy D; Lesyk R; Szychowski KA
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164157
[TBL] [Abstract][Full Text] [Related]
13. Medicinal applications of coumarins bearing azetidinone and thiazolidinone moieties.
Patil SA; Patil SA; Fariyike T; Marichev KO; Heras Martinez HM; Bugarin A
Future Med Chem; 2021 Nov; 13(21):1907-1934. PubMed ID: 34468216
[TBL] [Abstract][Full Text] [Related]
14. Biologically active 4-thiazolidinones: a review of QSAR studies and QSAR modeling of antitumor activity.
Devinyak O; Zimenkovsky B; Lesyk R
Curr Top Med Chem; 2012; 12(24):2763-84. PubMed ID: 23368102
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinone/thiazole based hybrids - New class of antitrypanosomal agents.
Kryshchyshyn A; Kaminskyy D; Karpenko O; Gzella A; Grellier P; Lesyk R
Eur J Med Chem; 2019 Jul; 174():292-308. PubMed ID: 31051403
[TBL] [Abstract][Full Text] [Related]
16. Molecular Modeling Studies on Some Important Anticancer Heterocycles: An Overview.
Kale M; Sonwane G; Nawale R; Mourya V
Curr Comput Aided Drug Des; 2018; 14(3):178-190. PubMed ID: 29564984
[TBL] [Abstract][Full Text] [Related]
17. Optimization of 2-(3-(arylalkyl amino carbonyl) phenyl)-3-(2-methoxyphenyl)-4-thiazolidinone derivatives as potent antitumor growth and metastasis agents.
Wu J; Yu L; Yang F; Li J; Wang P; Zhou W; Qin L; Li Y; Luo J; Yi Z; Liu M; Chen Y
Eur J Med Chem; 2014 Jun; 80():340-51. PubMed ID: 24794770
[TBL] [Abstract][Full Text] [Related]
18. Anticancer properties of 4-thiazolidinone derivatives depend on peroxisome proliferator-activated receptor gamma (PPARγ).
Szychowski KA; Leja ML; Kaminskyy DV; Kryshchyshyn AP; Binduga UE; Pinyazhko OR; Lesyk RB; Tobiasz J; Gmiński J
Eur J Med Chem; 2017 Dec; 141():162-168. PubMed ID: 29031063
[TBL] [Abstract][Full Text] [Related]
19. Study of antineoplastic action of novel isomeric derivatives of 4-thiazolidinone.
Chumak VV; Fil MR; Panchuk RR; Zimenkovsky BS; Havrylyuk DY; Lesyk RB; Stoika RS
Ukr Biochem J; 2014; 86(6):96-105. PubMed ID: 25816610
[TBL] [Abstract][Full Text] [Related]
20. Chromones: Privileged scaffold in anticancer drug discovery.
Patil VM; Masand N; Verma S; Masand V
Chem Biol Drug Des; 2021 Nov; 98(5):943-953. PubMed ID: 34519163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
